When cell and gene therapies surge to market, how resilient will your cell sourcing infrastructure be?

For the development of effective cell and gene therapies, access to high-quality source material is critical. Any misstep in this area can mean significant, costly setbacks and delays. Optimizing the identifications, sourcing, collection and delivery of allogeneic donor starting material is therefore of critical importance.

Learn how the industry can add capacity, build efficiencies and alleviate bottlenecks within the cell harvest infrastructure, ensuring high-quality starting material is available whenever and wherever it’s needed. Additionally, strategic and practical keys to working effectively with collaborative partners in this vitally important endeavor will be shared.

During this webinar, attendees will grow their knowledge and understanding of:

  • What exactly constitutes ‘quality’ in the context of critical starting materials for allogeneic cell therapy
  • Specific risks and practical repercussions downstream of insufficient/variable critical starting material quality, both for cell therapy manufacture and for success of the final product.
  • How to ensure both high quality and consistency of critical starting materials by building efficiencies into, and alleviating bottlenecks within, the cell harvest infrastructure
  • Critical considerations when determining an optimal starting material supplier.
  • Considerations of supplying quality source material during the COVID-19 pandemic and implementing key strategies to ensure delivery of therapies to patients
watch now
Watch the webinar on demand
Joy Aho

Joy Aho

Senior Product Manager, Be The Match BioTherapies

Joy Aho, PhD, is the Senior Product Manager at Be The Match BioTherapies®, where she develops innovative products and best-in-class services for the cell and gene therapy industry. Prior to joining the team, she worked in product development and management at Bio-Techne for 13 years designing pioneering clinical and discovery tools for the development of cell and gene therapies. Aho received her PhD in Molecular, Cellular, and Developmental Biology & Genetics from the University of Minnesota, and her research led her to studying the role of TGFβ family proteins during embryonic development utilizing stem cells and developmental models.

Dr. Sumithira Vasu

Dr. Sumithira Vasu


Sumithira Vasu, MBBS, is an Associate Professor in Hematology at The Ohio State University. Her research focus is on cell-based immunotherapies for acute myeloid leukemia and myelodysplastic syndrome.

Dr. Vasu also serves as the scientific director of the Blood and Marrow Transplantation Program and as medical director of the Cell Therapy Lab, Blood and Marrow Transplantation Section at the Arthur G. James Cancer Hospital. She has co-authored numerous articles in well-respected publications, including New England Journal of Medicine, Biology of Blood and Marrow Transplantation, Leukemia & Lymphoma, Blood and Bone Marrow Transplantation. Dr. Vasu is the National Co-Chair of BMT CTN 1803, a clinical protocol evaluating whether infusion of donor-derived NK cells peri-haplo BMT reduces relapse in patients with AML and MDS.

Emma Bjorgum

Emma Bjorgum

Director of Client Development, Aldevron
Arsalan Arif

arsalan arif

Founder & CEO, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.